

A NEW GROUP OF ANTIBIOTICS, HYDROXAMIC ACID ANTIMYCOTIC ANTIBIOTICS

II. THE STRUCTURE OF NEOENACTINS NL₁ AND NL₂ AND STRUCTURE-ACTIVITY RELATIONSHIP

HIROMASA OKADA, KATSUMI YAMAMOTO, SAYURI TSUTANO, YOSHIO INOUE
and SHOSHIRO NAKAMURA*

Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine,
1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan

JUN FURUKAWA

Institute of Applied Microbiology, University of Tokyo,
1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan

(Received for publication June 30, 1988)

The structures of neoenactins (NEs) NL₁ and NL₂, novel antimycotic antibiotics produced by *Streptovercillium olivoreticuli* in a precursor-oriented fashion, were elucidated by ¹H and ¹³C NMR and mass spectroscopic studies. The structures of both antibiotics are closely related to that of NE-A, the major component of NE congeners, being classified in the group of hydroxamic acid antimycotic antibiotics in which L-serine and a diketo amine form a hydroxamic acid structure.


To study the role of the carbonyl groups in the biological activities of the hydroxamic acid antimycotic antibiotics, NE-A was modified by reaction with various carbonyl reagents. In terms of antimycotic activity, the derivatives are classified into two distinct groups; the first ones are fairly comparable to but not exceeding and the second ones are less active than NE-A depending on their tendency to revert to NE-A by hydrolysis. In general, the biological activities of the derivatives are inversely proportional to their stabilities to hydrolysis.

Enactins (ENs) produced by *Streptomyces roseoviridis*¹⁾ and neoenactins (NEs) produced by *Streptovercillium olivoreticuli* subsp. *neoenacticus*^{2,3)} are antimycotic antibiotics potentiating activities of polyene antifungal antibiotics and antitumor agents such as bleomycin and vincristine⁴⁾. NEs are composed of several congeners which share similar physico-chemical and biological properties. The isolation and structural elucidation of NE-A (III), the main component, as well as those of NE-B₁, -B₂, -M₁ (lipoxamycin) and M₂ have been reported⁵⁻⁹⁾ and their structures are summarized in Fig. 1. In common, they contain L-serine as part of a hydroxamic acid moiety. Similar structural properties have been observed with the congeners of ENs. Therefore, we proposed the group name hydroxamic acid antimycotic antibiotics (HAAA) for ENs and NEs¹⁰⁾.

Recently, we isolated novel members of HAAA, named NE-NL₁ (I) and -NL₂ (II), during a study of the biosynthesis of NEs¹¹⁾. The effect of supplementation of individual amino acids at a final concentration of 0.1% to the basal medium, from which nitrogen source was reduced by 90%, on the production of NEs was studied quantitatively and qualitatively. When L-norleucine was used as an amino acid supplement, I and II were produced in rather high yields and their preliminary physico-chemical and biological properties have been reported¹¹⁾.

Since the mono and bis-2,4-dinitrophenyl (DNP)-derivatives (Fig. 1) were inactive against

Fig. 1. Structures of neoenactin congeners and neoenactin A derivatives.



Compound	R ₁	R ₂	X	Y	R ₃	R ₄	R ₅
NE-NL ₁ (I)	H	H	=O	=O	H	H	H
Bis-DNP-NE-NL ₁ (Ia)			=O	=O	H	H	H
	(DNP)	(DNP)					
NE-NL ₂ (II)	H	H	=O	=O	H	H	C ₂ H ₅
Bis-DNP-NE-NL ₂ (IIa)	DNP	DNP	=O	=O	H	H	C ₂ H ₅
NE-A (III)	H	H	=O	=O	H	H	CH ₃
Bis-DNP-NE-A (IIIa)	DNP	DNP	=O	=O	H	H	CH ₃
Mono-DNP-NE-A (IIIb)	DNP	H	=O	=O	H	H	CH ₃
NE-M ₁	H	H	=O	=O	CH ₃	H	H
NE-M ₂	H	H	=O		H	H	CH ₃
NE-B ₁	H	H	=O	=O	CH ₃	H	CH ₃
NE-B ₂	H	H	=O	=O	H	CH ₃	CH ₃
IIIc	H	H	=NNHCONH ₂	=NNHCONH ₂	H	H	CH ₃
III d	H	H	=NNHCONHC ₆ H ₅	=NNHCONHC ₆ H ₅	H	H	CH ₃
III e	H	H	=NNHCOOC ₂ H ₅	=NNHCOOC ₂ H ₅	H	H	CH ₃
III f	H	H	=NOH	=NOH	H	H	CH ₃
III g	H	H	=NOCH ₃	=NOCH ₃	H	H	CH ₃
III h	H	H	=NOCH ₂ C ₆ H ₄ NO ₂	=NOCH ₂ C ₆ H ₄ NO ₂	H	H	CH ₃

Candida albicans in vitro (data not shown), the free $-\text{NH}_2$ and $>\text{NOH}$ groups appeared to be essential to the biological activity. In attempts to study structure-activity relationships, two carbonyl groups at 7- and 14-positions of **III** were simultaneously modified with a series of carbonyl reagents.

In this report, the structural elucidation of **I** and **II**, and the comparative study on the biological activities of the NE-A derivatives are concerned.

Structural Elucidation of NE-NL₁ and -NL₂

The existence of a free hydroxamic acid-type structure in **I** and **II** was strongly suggested by the positive FeCl_3 test. Further, the recovery of L-serine from the acid hydrolysates of **I** and **II** was proven by HPLC on a enantiomeric resolution column (TSK gel Enantio L2, 4.6×150 mm, Tosoh Co., Ltd., Tokyo) using 0.5 mM CuSO_4 as a mobile phase. Both **I** and **II** were converted to the corresponding stable bis-DNP-derivatives according to the previous method⁹⁾ [**Ia** (mp 140°C) and **IIa** (mp 145°C), respectively]. The molecular formula $\text{C}_{18}\text{H}_{34}\text{N}_2\text{O}_6$ and $\text{C}_{20}\text{H}_{38}\text{N}_2\text{O}_6$ were proposed for **I** and **II**, respectively, based on the results of fast atom bombardment (FAB)-MS of **I** and **II**, and ^1H and ^{13}C NMR spectra of **Ia** and **IIa**¹¹⁾. Since the molecular formula $\text{C}_{19}\text{H}_{38}\text{N}_2\text{O}_6$ had been reported for **III**⁹⁾, **I** and **II** can be considered to contain one more and less CH_2 group, respectively, when compared with **III**.

The ^1H NMR data (400 MHz, CDCl_3) of **Ia** and **IIa** and their assignments are presented in Table 1 in comparison with those of **IIIa**. The data of **Ia**, **IIa** and **IIIa** are almost identical except that eight, twelve and ten methylene proton signals are observed for **Ia**, **IIa** and **IIIa**, respectively, in the methylene proton region (δ 1.25~1.27). The existence of only one methyl group adjacent to CH_2 in **Ia**, **IIa** and **IIIa** is also shown by the chemical shift (3H, t, $J=6.8\sim 7.0$ Hz), whereas the existence of any other methyl groups on tertiary or quaternary carbon atoms can be excluded. One of the carbonyl groups of **I** can be located at the 14-position by the fragment peaks at m/z 99.0810 (calcd for $\text{C}_6\text{H}_{11}\text{O}^+$: 99.0809) and m/z 71.0856 (calcd for $\text{C}_6\text{H}_{11}^+$: 71.0861) in high-resolution electron impact (HREI)-MS spectrum of **Ia**. Further, the fragment peak of **IIa** at m/z 127.1124 (calcd for $\text{C}_6\text{H}_{15}\text{O}^+$: 127.1123) postulated that one of the carbonyl groups is also located at 14-position in **II**. The ^{13}C NMR data (100 MHz, CDCl_3) of **Ia** and **IIa** and their assignments are shown in Table 2 together with those of **IIIa**⁷⁾. Thus, the structures of **I** and **II** are elucidated as shown in Fig. 1.

Synthesis of NE-A Derivatives (**IIIc**~**IIIh**)

A mixture of **III** (20 mg, 0.052 mmol) in dry MeOH (1 ml) and a carbonyl reagent (0.11 mmol) was kept at room temperature for 0.6~2 hours. The reaction was monitored intermittently by Silica gel TLC (Kieselgel 60F₂₅₄ plate; 0.25 mm thickness, E. Merck, Darmstadt) using CHCl_3 - MeOH - H_2O (12:6:1) as a developing solvent and 5% FeCl_3 aqueous solution for detection until the spot of **III** disappeared. The pH of the reaction mixture was adjusted to 3 by adding 5% HCl - MeOH in the case of ethyl carbazate. The summary of the purification of the various analogues is shown in Table 3. The products were purified by silica gel column chromatography developed with CHCl_3 - MeOH (9:1, Method A) or CHCl_3 - MeOH (19:1, Method B), or repeated recrystallization from MeOH (Method C).

The purity of NE-A derivatives was examined by silica gel TLC or HPLC on Radial Pak Nova Pak C₁₈ (8×100 mm, Waters Assoc., Mass.) using MeOH - 0.05 M KH_2PO_4 (3:2, pH 2.8) as a mobile phase; the latter system was also used for the determination of **III** and **IIIc**.

Based on the MS data shown in Table 3, both of the carbonyl groups at 7- and 14-positions were

Table 1. ^1H NMR data (400 MHz, CDCl_3) of bis-DNP-derivatives of neoenactins A, NL_1 and NL_2 .

Assignment (position)	Chemical shift (δ)		
	IIIa (50°C)	Ia (27°C)	IIa (27°C)
CH_2CH_3	0.87 (3H, t, $J=6.8$, 20-H)	0.88 (3H, t, $J=7.0$, 19-H)	0.87 (3H, t, $J=7.0$, 21-H)
CH_2	1.27 (10H, m, 10, 11, 17, 18, 19-H)	1.26 (8H, m, 10, 11, 17, 18-H)	1.25 (12H, m, 10, 11, 17, 18, 19, 20-H)
$\text{CH}_2\text{CH}_2\text{CO}$ (9, 12, 16)	1.55 (6H, m)	1.51 (6H, m)	1.53 (6H, m)
CH_2CO (8, 13, 15)	2.41 (6H, m)	2.40 (6H, m)	2.40 (6H, m)
$\text{NCH}_2\text{CH}_2\text{CO}$ (6)	2.83 (2H, t, $J=5.9$)	2.85 (2H, t, $J=5.6$)	2.85 (2H, t, $J=5.9$)
$\text{NCH}_2\text{CH}_2\text{CO}$ (5)	4.03 (1H, dt, $J=14.8, 5.9$), 4.24 (1H, dt, $J=14.8, 5.9$)	4.03 (1H, dt, $J=14.4, 5.6$), 4.29 (1H, dt, $J=14.4, 5.6$)	4.01 (1H, dt, $J=15.0, 5.9$), 4.28 (1H, dt, $J=15.0, 5.9$)
HOCH_2 (1)	4.09 (1H, ddd, $J=5.5, 5.6, 11.8$), 4.13 (1H, ddd, $J=5.5, 5.6, 11.8$)	4.09 (1H, ddd, $J=5.2, 5.2, 11.8$), 4.18 (1H, ddd, $J=5.2, 5.2, 11.8$)	4.09 (1H, ddd, $J=5.5, 5.5, 11.0$), 4.17 (1H, ddd, $J=5.5, 5.5, 11.0$)
NHCHCO (2)	4.86 (1H, br m)	4.88 (1H, br m)	4.87 (1H, br m)
$H\text{-Ar}$ (6')	6.88 (1H, d, $J=9.0$)	6.89 (1H, d, $J=9.5$)	6.88 (1H, d, $J=9.0$)
$H\text{-Ar}$ (6'')	7.60 (1H, d, $J=9.0$)	7.64 (1H, d, $J=9.5$)	7.62 (1H, d, $J=9.0$)
$H\text{-Ar}$ (5')	8.27 (1H, dd, $J=2.8, 9.0$)	8.24 (1H, dd, $J=2.5, 9.5$)	8.26 (1H, dd, $J=2.4, 9.0$)
$H\text{-Ar}$ (5'')	8.52 (1H, dd, $J=2.8, 9.0$)	8.53 (1H, dd, $J=2.5, 9.5$)	8.52 (1H, dd, $J=2.4, 9.0$)
$H\text{-Ar}$ (3')	9.12 (1H, d, $J=2.8$)	9.10 (1H, d, $J=2.5$)	9.07 (1H, d, $J=2.4$)
$H\text{-Ar}$ (3'')	8.95 (1H, d, $J=2.8$)	8.94 (1H, d, $J=2.5$)	8.94 (1H, d, $J=2.4$)
CNHAr	9.18 ^a (1H, d)	9.17 ^a (1H, d)	9.17 ^a (1H, d)

^1H NMR spectra were recorded on a Jeol GX 400 spectrometer. TMS (0 ppm) was used as an internal standard. Number of protons, multiplicity, coupling constants in Hz and position of protons where necessary are indicated in parenthesis.

^a Temperature dependent.

Table 2. ^{13}C NMR data (100 MHz, 50°C , CDCl_3) of bis-DNP-derivatives of neoenactins A, NL_1 and NL_2 .

Position	Chemical shift (δ)			Position	Chemical shift (δ)		
	IIIa	Ia	IIa		IIIa	Ia	IIa
C-1	62.08	62.20	62.30	C-18	31.58	22.37	29.03
C-2	56.17	56.33	56.30	C-19	22.47	13.77	31.70
C-3	172.50	172.44	172.57	C-20	13.99		22.57
C-5	43.50	43.81	43.83	C-21			13.95
C-6	38.76	38.76	38.80	C-1'	146.63 ^e	146.72 ^e	146.68 ^e
C-7	208.37	208.05	208.07	C-2'	131.53 ^e	131.70 ^e	131.83 ^e
C-8	42.86 ^a	42.85 ^a	42.94 ^a	C-3'	124.22	124.07	124.16
C-9	23.36 ^b	23.45 ^b	23.47 ^b	C-4'	137.10 ^e	137.26 ^e	137.44 ^e
C-10	28.72	28.78	28.78	C-5'	130.48	130.38	130.45
C-11	28.72	28.78	28.78	C-6'	113.97	114.09	113.98
C-12	23.19 ^b	23.28 ^b	23.30 ^b	C-1''	154.85	154.91	154.87
C-13	42.53 ^a	42.50 ^a	42.53 ^a	C-2''	137.28 ^e	137.40 ^e	137.44 ^e
C-14	212.08	211.60	211.63	C-3''	122.81	122.65	122.71
C-15	42.92	42.85	42.94	C-4''	143.01 ^e	143.15 ^e	143.22 ^e
C-16	23.84	23.58	23.98	C-5''	129.92	129.76	129.76
C-17	28.91	31.43	29.26	C-6''	115.43	115.56	115.47

^{13}C NMR spectra were recorded on a Jeol GX 400 spectrometer.

TMS (0 ppm) was used as an internal standard.

^{a-c} Values with identical superscript within a column may be interchanged.

Table 3. Synthesis and purification of neoenactin A derivatives.

Compound	Reagent	Reaction time (hours)	Rf values on TLC		Method of purification	Yield (%)	MS m/z (M+H)
			I ^a	II ^b			
III			0.32	0.45			
IIIc	$\text{H}_2\text{NNHCONH}_2 \cdot \text{HCl}$	1.5	0.24	0.37	A ^c	42	487 (FAB)
III _d	$\text{H}_2\text{NNHCONHC}_6\text{H}_5 \cdot \text{HCl}$	1.5	0.46	0.53	C ^e	59	639 (FAB, FD)
III _e	$\text{H}_2\text{NNHCOOC}_2\text{H}_5$	2.0	0.48	0.53	B ^d	53	545 (FAB)
III _f	$\text{H}_2\text{NOH} \cdot \text{HCl}$	0.6	0.26	0.39	A+HPLC ^f	36	403 (FAB, FD)
III _g	$\text{H}_2\text{NOCH}_3 \cdot \text{HCl}$	2.8	0.49	0.53	B	67	431 (FAB)
III _h	$\text{H}_2\text{NOCH}_2\text{C}_6\text{H}_4\text{NO}_2 \cdot \text{HCl}$	2.0	0.59	0.61	A	20	673 (FAB)

^a Kieselgel 60F₂₅₄ plate; 0.25 mm thickness, E. Merck, Darmstadt, solvent: CHCl_3 - MeOH (2:1).

^b Kieselgel 60F₂₅₄ plate; 0.25 mm thickness, E. Merck, Darmstadt, solvent: CHCl_3 - MeOH - H_2O (12:6:1).

^c Silica gel column chromatography, solvent: CHCl_3 - MeOH (9:1).

^d Silica gel column chromatography, solvent: CHCl_3 - MeOH (19:1).

^e Repeated crystallization from MeOH.

^f Radial Pak Nova Pak C₁₈ Cartridge (8 × 100 mm), mobile phase: MeOH - 0.05 M KH_2PO_4 (3:2, pH 2.8), flow rate: 2.0 ml/minute.

confirmed to be substituted with individual carbonyl reagents in all the cases, and the structures shown in Fig. 1 were proposed, though the geometrical structures at 7- and 14-positions still remained to be solved.

Antimicrobial Activity of NE-A Derivatives

The antimicrobial activities of the NE-A derivatives were studied in comparison with that of III and the results are summarized in Table 4. The derivatives III_c and III_e were as potent as III, whereas the antimicrobial activities of III_d, III_f, III_g and III_h were negligible. In general, the hydrazone type

Table 4. Antimicrobial spectra of neoenactin A derivatives.

Test organism	MIC ($\mu\text{g/ml}$)						
	III	IIIc	IIIId	IIIe	IIIf	IIIg	IIIh
<i>Candida tropicalis</i> NI 7495	0.05	0.39	25	0.39	3.13	3.13	50
<i>C. pseudotropicalis</i> NI 7494	0.095	0.095	1.56	0.095	0.78	0.78	12.5
<i>C. albicans</i> Yu 1200	0.78	0.39	50	0.78	3.13	12.5	50
<i>C. albicans</i> MTU 12013	0.39	0.39	25	0.78	1.56	12.5	25
<i>Saccharomyces cerevisiae</i>	0.19	0.095	12.5	0.19	0.39	0.39	12.5
<i>Alternaria kikuchiana</i>	1.56	0.39	25	0.78	6.25	12.5	50
<i>Glomerella cingulata</i>	0.39	0.047	0.78	<0.024	3.13	3.13	>50
<i>Gloeosporium laeticolor</i>	0.78	0.39	25	0.39	6.25	25	>50
<i>Trichophyton mentagrophytes</i> (833)	3.13	1.56	50	1.56	6.25	6.25	>50
<i>Aspergillus niger</i> F-16	>50	50	>50	50	50	25	50
<i>Pyricularia oryzae</i>	0.19	0.19	12.5	0.19	0.39	0.78	25
<i>Helminthosporium oryzae</i>	0.19	0.05	1.56	0.095	0.78	3.13	25

MICs were determined by the agar dilution method on glucose nutrient agar.

Table 5. Stability of neoenactin A semicarbazone.

Time (hours)	III ($\mu\text{g/ml}$)/IIIc ($\mu\text{g/ml}$)					
	MeOH	H ₂ O	pH 2.8	pH 5.0	pH 6.0	pH 7.5
0	0/250	0/250	30/200	40/210	0/250	0/250
4	50/200	110/100	190/ 20	150/ 40	120/ 60	70/150
18	60/170	130/ 20	200/ 20	130/ 20	100/ 20	60/ 20

The semicarbazone IIIc was dissolved in MeOH, H₂O or 1/30 M phosphate buffer of different pH's at the concentration of 250 $\mu\text{g/ml}$ and kept at room temperature for the period indicated. The concentrations of III and IIIc in the solution was determined by HPLC on a Radial Pak Nova Pak C₁₈ cartridge eluted with MeOH - 0.05 M KH₂PO₄ (3:2, pH 2.8) at a flow rate of 2.7 ml/minute. The retention times of III and IIIc were 9.1 and 7.3 minutes, respectively.

derivatives (IIIc~IIIe) were more active than the oxime type derivatives (IIIf~IIIh) except for IIIId which was hardly soluble in water and organic solvents such as MeOH and CHCl₃.

Stability of NE-A Derivatives

The stability of IIIc in various solvents is shown in Table 5. The semicarbazone IIIc proved to be stable in MeOH but not in H₂O, especially at acidic pH, being almost completely converted to III at room temperature within 4 hours. The loss in a combined amount of III and IIIc from the original one of IIIc at neutral and alkaline pH's might result from easy decomposition of III at pH's in this range. In contrast, the conversion to III from IIIg, a representative of the oxime type derivatives, was less than 1% in 1/30 M phosphate buffer (pH 6.0) even after 18 hours (data not shown). Based on these observations and the results for the other derivatives, the antimicrobial activities of the NE-A derivatives seemingly depend on their tendency to be hydrolyzed to III which, in turn, inhibits the growth of *C. albicans*.

Discussion

As described above, the existence of free -NH₂ and >NOH groups appears to be essential for the biological activity of III. L-Serine hydroxamic acid was also inactive at concentrations as high as 100 $\mu\text{g/ml}$, implying the important role of the diketo amine moiety. In the present paper, it was confirmed that the carbonyl groups at the 7- and 14-positions were required for III to exhibit antimycotic

activity. Because NE-M₂, in which the carbonyl group at the 14-position is reduced to the hydroxyl group, is as potent as III, the function of the carbonyl group at the 14-position still remains to be elucidated.

Acknowledgment

The present work was supported in part by a Grant-in-Aid for Co-operative Research from the Ministry of Education, Science and Culture, Japan. The authors wish to thank Dr. K. SAKANO of Daiichi Seiyaku Co., Ltd., Tokyo, for his help in measuring MS data.

References

- 1) OTANI, T.; S. ARAI, K. SAKANO, Y. KAWAKAMI, K. ISHIMARU, H. KONDO & S. NAKAMURA: H 646-SY3 substance, a potentiator for polyene antifungal antibiotic. *J. Antibiotics* 30: 182~185, 1977
- 2) KONDO, H.; H. SUMOMOI, T. OTANI & S. NAKAMURA: Neo-enactin, a new antifungal antibiotic potentiating polyene antifungal antibiotics. I. Fermentation, extraction, purification and physico-chemical and biological properties. *J. Antibiotics* 32: 13~17, 1979
- 3) OTANI, T.; K. ISHIMARU, Y. KAWAKAMI, H. YOSHIYAMA, H. KONDO & S. NAKAMURA: Neo-enactin, a new antifungal antibiotic potentiating polyene antifungal antibiotics. II. Taxonomic studies of the producing microorganism and simultaneous production of bleomycin group and streptothricin-like antibiotics. *Jpn. J. Antibiotics* 32: 720~728, 1979
- 4) KASAI, S.; S. NAKAMURA, T. KUNIMOTO & K. NITTA: Action of a new antibiotic, neo-enactin, on the cell membrane and its application to combination treatment in a cultured tumor cell system. *Gann* 73: 649~655, 1982
- 5) NISHIO, M.; N. YASUDA & S. NAKAMURA: Neo-enactins A, B₁ and B₂, new antifungal antibiotics potentiating polyene antifungal antibiotics. *J. Antibiotics* 36: 1399~1401, 1983
- 6) ROY, S. K.; S. NAKAMURA, J. FURUKAWA & S. OKUDA: The structure of neo-enactin A, a new antifungal antibiotic potentiating polyene antifungal antibiotics. *J. Antibiotics* 39: 717~720, 1986
- 7) ROY, S. K.; Y. INOUE, S. NAKAMURA, J. FURUKAWA & S. OKUDA: Isolation, structural elucidation and biological properties of neoactins B₁, B₂, M₁ and M₂, neoactin congeners. *J. Antibiotics* 40: 266~274, 1987
- 8) WHALEY, H. A.; O. K. SEBEK & C. LEWIS: Production, isolation, characterization, and evaluation of lipoxamycin, a new antifungal agent. *Antimicrob. Agents Chemother.*-1970: 455~461, 1971
- 9) WHALEY, H. A.: The structure of lipoxamycin, a novel antifungal antibiotic. *J. Am. Chem. Soc.* 93: 3767~3769, 1971
- 10) INOUE, Y.; H. OKADA & S. NAKAMURA: Hydroxamic acid antimycotic antibiotics, a new group of antibiotics. *Ann. N.Y. Acad. Sci.*, in press
- 11) OKADA, H.; K. YAMAMOTO, S. TSUTANO & S. NAKAMURA: A new group of antibiotics, hydroxamic acid antimycotic antibiotics. I. Precursor-initiated changes in productivity and biosynthesis of neoactins NL₁ and NL₂. *J. Antibiotics* 41: 869~874, 1988